Zepbound denial: how to appeal a tirzepatide weight-management or OSA denial

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults who meet BMI criteria, and for moderate-to-severe obstructive sleep apnea in adults with obesity. As with other weight-loss GLP-1s, a contractual exclusion is rarely appealable on medical necessity, and an unmet-criteria denial often is. The OSA indication is distinctive — it can be a separately coverable medical basis when weight-loss coverage is excluded.

How Zepbound is covered

For weight management, plans that cover anti-obesity drugs generally require a BMI of 30 or higher (or 27 or higher with a comorbidity), lifestyle intervention, and sometimes step therapy. For the OSA indication, documentation of moderate-to-severe obstructive sleep apnea (typically a sleep study) plus obesity supports a distinct medical-necessity basis.

Why Zepbound claims get denied

• The plan excludes weight-loss drugs by contract.
• BMI or comorbidity criteria weren't documented to threshold.
• Step therapy or lifestyle-intervention requirement not met/documented.
• OSA indication not supported with a sleep study or severity documentation.
• Prior authorization missing or incomplete.

Is a Zepbound denial worth appealing?

How to appeal a Zepbound denial

1. 1

   Pick the strongest indication

   If weight-loss coverage is excluded, lead with the OSA indication where it applies — it's a medical basis that can survive a weight-loss exclusion.

2. 2

   Attach the objective evidence

   For OSA, the sleep study and severity; for weight management, the BMI, comorbidities, and lifestyle-intervention record.

3. 3

   Clear prior auth and step therapy

   Supply the authorization details and document any required step or a contraindication to it.

Zepbound — frequently asked

FDA-approved indications and payer prior-authorization criteria are paraphrased for plain-language reference, not reproduced verbatim, and vary by plan. This is general information, not medical, legal, or coverage advice — confirm against the current FDA label, the plan's policy, and the patient's benefit documents.